论文部分内容阅读
[目的] 评价肝纤方联合拉米夫定治疗慢性乙型肝炎肝纤维化的疗效。[方法] 采用肝纤方(制大黄、鳖甲、首乌、赤芍等)联合拉米夫定治疗慢性乙型肝炎72例,并与单用拉米夫定治疗 86 例随机对照观察 2 a。[结果]联合治疗组治疗后患者各项肝纤维化指标下降幅度明显大于单用拉米夫定治疗组(P<0.01或<0.05)。[结论]联合用药更有利于阻断或逆转肝纤维化的形成与发展,具有一定的临床试用价值。
[Objective] To evaluate the curative effect of Hepatic fibrosis combined with lamivudine in treating chronic hepatitis B liver fibrosis. [Method] 72 cases of chronic hepatitis B were treated with Hepatic fibrosis (rhubarb, turtle shell, Radix Polygoni multiflori, radix paeoniae rubra, etc.) combined with lamivudine, and 86 cases were treated with lamivudine alone for 2 years . [Results] The decrease of hepatic fibrosis index in the combination therapy group was significantly greater than that in the lamivudine therapy group alone (P <0.01 or <0.05). [Conclusion] The combination therapy is more conducive to blocking or reversing the formation and development of liver fibrosis, and has certain clinical trial value.